Login to Your Account

Pharma: Other news to note

Tuesday, June 10, 2014
Teva Pharmaceutical Industries Ltd., of Jerusalem, said the FDA has expanded the indication for Azilect (rasagiline tablets) from monotherapy and adjunct to levodopa to now include adjunct to dopamine agonists.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription